GILD
Gilead Sciences, Inc.
Stock
$149.05−2.23 (−1.47%)Close Sep 30, 2026
| Shareholders' equity (Q2 2026) | YoY | 5-year CAGR | 10-year CAGR |
|---|---|---|---|
| $11.8B | −39.9% | 4.5% | 2.0% |
| Shareholders' equity (Q2 2026) | $11.8B |
|---|---|
| YoY | −39.9% |
| 5-year CAGR | 4.5% |
| 10-year CAGR | 2.0% |
Shareholders' equity
| Period | Equity | YoY |
|---|---|---|
| 2025 | $22.7B | +17.4% |
| 2024 | $19.3B | −15.3% |
| 2023 | $22.8B | +7.5% |
| 2022 | $21.2B | +0.8% |
| 2021 | $21.1B | +15.8% |
| 2020 | $18.2B | −19.2% |
| 2019 | $22.5B | +5.3% |
| 2018 | $21.4B | +4.6% |
| 2017 | $20.4B | +8.2% |
| 2016 | $18.9B | +1.9% |
| 2015 | $18.5B | +20.1% |
| 2014 | $15.4B | +35.7% |
| 2013 | $11.4B | +22.2% |
| 2012 | $9.3B | +38.0% |
| 2011 | $6.7B | +14.9% |
| 2010 | $5.9B | −7.9% |
| 2009 | $6.4B | +49.0% |
| 2008 | $4.3B | +13.9% |
| 2007 | $3.8B | — |